Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18926867 | STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON | October 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18742810 | SYSTEMS AND METHODS FOR CONTINUOUS CULTIVATION AND RECOVERY OF COMESTIBLE NON-HUMAN ANIMAL CELLS | June 2024 | November 2025 | Allow | 17 | 3 | 1 | Yes | No |
| 18591883 | STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON | February 2024 | September 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18590541 | MEDIUM, METHODS, CELLS AND SECRETED FACTORS FOR STEM CELL CULTURE AND THERAPY | February 2024 | October 2025 | Allow | 20 | 1 | 0 | No | No |
| 18584039 | METHOD OF PREPARING A THREE-DIMENSIONAL SCAFFOLD FOR CELL CULTURE | February 2024 | November 2025 | Allow | 21 | 3 | 0 | No | No |
| 18582113 | BIOSYNTHETIC DEVICES | February 2024 | August 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18394522 | HARVESTING CELL-BASED MEAT | December 2023 | March 2024 | Allow | 3 | 1 | 0 | No | No |
| 18387555 | XENOTRANSPLANTATION PRODUCTS AND METHODS | November 2023 | June 2025 | Allow | 19 | 1 | 0 | No | No |
| 18470861 | Expanding Cells In A Bioreactor | September 2023 | March 2025 | Allow | 18 | 1 | 0 | No | No |
| 18239216 | INJECTABLE HYDROGEL FOR TREATMENT OF SEGMENTAL BONE DEFECT | August 2023 | December 2024 | Allow | 16 | 1 | 1 | No | No |
| 18351804 | WET PRESERVATION OF TISSUE | July 2023 | April 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18351488 | 3-DIMENSIONAL (3D) TISSUE-ENGINEERED MUSCLE FOR TISSUE RESTORATION | July 2023 | April 2025 | Allow | 21 | 1 | 1 | No | No |
| 18347142 | COMPOSITION FOR CULTURING BRAIN ORGANOID BASED ON DECELLULARIZED BRAIN MATRIX AND METHOD FOR PREPARING SAME | July 2023 | February 2026 | Allow | 31 | 3 | 0 | No | No |
| 18319679 | TRANSCRIPTION FACTORS CONTROLLING DIFFERENTIATION OF STEM CELLS | May 2023 | January 2026 | Abandon | 32 | 1 | 1 | No | No |
| 18314451 | Expanding Cells In A Bioreactor | May 2023 | November 2025 | Allow | 30 | 1 | 0 | Yes | No |
| 18034564 | HYDROGEL STRUCTURE, METHOD FOR PRODUCING HYDROGEL STRUCTURE, AGENT, AND TRANSPLANTATION METHOD | April 2023 | March 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18140279 | METHODS FOR CULTURING HUMAN KERATINOCYTES | April 2023 | September 2025 | Abandon | 29 | 0 | 1 | No | No |
| 18306152 | MICROBEADS FOR CELL CULTURE AND METHOD OF MONITORING CELL CULTURE USING THE SAME | April 2023 | May 2025 | Allow | 25 | 1 | 0 | No | No |
| 18133843 | ENCAPSULATED CELLS AND METHODS OF PRESERVING THEREOF | April 2023 | March 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18124741 | METHOD FOR DECELLULARIZATION OF SKIN TISSUE, METHOD FOR CONSTRUCTION OF ARTIFICIAL SKIN, METHOD FOR PREPARATION OF HYDROGEL OF DECELLULARIZED SKIN TISSUE, LYOPHILIZED, DECELLULARIZED SKIN TISSUE, AND BIOINK | March 2023 | December 2025 | Abandon | 33 | 1 | 1 | No | No |
| 18117915 | Devices And Methods For Mitochondria Replacement And For Generating Cellular Therapeutics | March 2023 | February 2026 | Allow | 35 | 1 | 1 | No | No |
| 18164308 | Methods For Development And Use Of Minimally Polarized Function Cell Micro-Aggregate Units In Tissue Applications Using LGR4, LGR5, And LGR6 Expressing Epithelial Stem Cells | February 2023 | July 2025 | Allow | 29 | 2 | 0 | No | No |
| 18100195 | Differentiation Method | January 2023 | October 2025 | Allow | 33 | 2 | 0 | Yes | No |
| 18156378 | CELL SEPARATION APPARATUS AND METHODS OF USE | January 2023 | October 2025 | Abandon | 33 | 2 | 0 | No | No |
| 18152470 | IN VITRO METHOD FOR CREATING A VIABLE CONNECTIVE TISSUE AND/OR OSSEOUS TISSUE | January 2023 | December 2024 | Allow | 23 | 1 | 0 | No | No |
| 18076785 | NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES | December 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17779991 | 3D scaffold comprising a biocompatible polymer with a colonization chamber open at the top for biological cells, and with a canal vessel surrounding the colonization chamber | November 2022 | September 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17971623 | Low-macrophage-adhesion/activation culture devices for continuous hematopoiesis and expansion of hematopoietic stem cells and progenitor cells | October 2022 | January 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18046678 | PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (NON-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAME | October 2022 | December 2024 | Allow | 27 | 1 | 0 | No | No |
| 17935334 | HARVESTING CELL-BASED MEAT | September 2022 | December 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17931674 | USE OF TERM AMNIOTIC FLUID CELLS FOR THE TREATMENT OF ACUTE AND CHRONIC RESPIRATORY DISEASES | September 2022 | February 2026 | Abandon | 41 | 2 | 1 | No | No |
| 17817051 | WET PRESERVATION OF TISSUE | August 2022 | August 2024 | Allow | 25 | 1 | 0 | No | No |
| 17870569 | METHOD FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELLS | July 2022 | April 2025 | Allow | 32 | 1 | 0 | No | No |
| 17791873 | COMPOSITIONS AND METHODS OF USE OF ONCOLYTIC VIRUS LIKE VESICLES | July 2022 | January 2026 | Allow | 43 | 2 | 1 | No | No |
| 17791498 | TARGETING TRANSFER RNA FOR THE SUPPRESSION OF NONSENSE MUTATIONS IN MESSENGER RNA | July 2022 | March 2026 | Abandon | 44 | 1 | 1 | No | No |
| 17850882 | CELL PREPARATION METHOD, CELL CULTIVATION DEVICE, AND KIT | June 2022 | January 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17841700 | CULTURE MEDIA, CELL CULTURES AND METHODS OF CULTURING PLURIPOTENT STEM CELLS IN AN UNDIFFERENTIATED STATE | June 2022 | October 2025 | Allow | 40 | 3 | 0 | No | No |
| 17827934 | BIOENERGETIC BONE | May 2022 | May 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17664194 | CELL CRYOPRESERVATION COMPOSITION AND CRYOPRESERVATION METHOD | May 2022 | June 2024 | Allow | 25 | 0 | 0 | No | No |
| 17736953 | PROCESSES FOR GENERATING TIL PRODUCTS ENRICHED FOR TUMOR ANTIGEN-SPECIFIC T-CELLS | May 2022 | March 2023 | Allow | 11 | 1 | 0 | No | No |
| 17736579 | DEVICES AND METHODS FOR DELIVERING THERAPEUTICS | May 2022 | August 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17723748 | Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5 and LGR6 Expressing Epithelial Stem Cells | April 2022 | November 2022 | Allow | 7 | 1 | 0 | No | No |
| 17689251 | SCAFFOLD-FREE 3D BIOPRINTING OF PORCINE CELLS | March 2022 | February 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17641250 | METHODS FOR DERIVING AUTOLOGOUS AND HYPOIMMUNOGENIC HAIR FOLLICLE CONTAINING SHEETS IN VITRO | March 2022 | April 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17687193 | FASL EXPRESSION AND FASR GENE KNOCKOUT TO PROTECT THERAPEUTIC CELLS FROM ALLOGENEIC REJECTION AND ACTIVATION-INDUCED CELL DEATH | March 2022 | December 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17585783 | METHODS OF TREATING OR PREVENTING AGE-RELATED DISORDERS | January 2022 | February 2026 | Allow | 49 | 2 | 0 | Yes | No |
| 17646539 | USE OF TERM AMNIOTIC FLUID CELLS FOR THE TREATMENT OF ACUTE AND CHRONIC RESPIRATORY DISEASES | December 2021 | August 2022 | Allow | 7 | 1 | 1 | Yes | No |
| 17544229 | Method of Increasing Bone Cell Viability | December 2021 | October 2025 | Abandon | 46 | 4 | 1 | Yes | No |
| 17532509 | TISSUE PRODUCTS WITH ACTIVE AGENTS AND METHODS OF PRODUCTION | November 2021 | August 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17528822 | CARDIOSPHERE-DERIVED CELLS AND EXOSOMES SECRETED BY SUCH CELLS IN THE TREATMENT OF MUSCULAR DYSTROPHY | November 2021 | June 2025 | Allow | 42 | 2 | 0 | No | No |
| 17609164 | Hair Follicle Primordia and Method for Producing Same | November 2021 | March 2026 | Allow | 52 | 3 | 1 | No | No |
| 17509260 | PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (NON-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAME | October 2021 | April 2022 | Allow | 5 | 1 | 0 | No | No |
| 17503634 | APPARATUS AND METHOD FOR ESTABLISHMENT OF INDUCED PLURIPOTENT STEM CELLS | October 2021 | September 2024 | Allow | 35 | 2 | 0 | Yes | No |
| 17409466 | METHOD OF TREATMENT | August 2021 | August 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17430648 | EXTRACELLULAR MATRIX-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME, AND THREE-DIMENSIONAL TISSUE CONSTRUCT AND METHOD FOR PRODUCING SAME | August 2021 | May 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17424199 | CLOSED-ENDED DNA (CEDNA) AND USE IN METHODS OF REDUCING GENE OR NUCLEIC ACID THERAPY RELATED IMMUNE RESPONSE | July 2021 | December 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17358618 | AAV Expression Cassette and AAV Vectors Comprising the Same | June 2021 | September 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17347077 | XENOTRANSPLANTATION PRODUCTS AND METHODS | June 2021 | July 2023 | Allow | 25 | 1 | 0 | No | No |
| 17341206 | Silica Encapsulated DNA on Magnetic Nanoparticles | June 2021 | November 2024 | Allow | 42 | 4 | 1 | Yes | No |
| 17298352 | HYDROGEL BIOMIMETIC FOR INVASIVE DISEASES | May 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17326734 | Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5 and LGR6 Expressing Epithelial Stem Cells | May 2021 | January 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17295453 | Fibroblast growth factor 21 (FGF21) gene therapy | May 2021 | February 2026 | Allow | 57 | 3 | 1 | No | No |
| 17244437 | COMPOSITIONS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIZING ENTEROCOLITIS IN INFANTS AND YOUNG CHILDREN | April 2021 | March 2025 | Allow | 46 | 4 | 0 | No | No |
| 17237336 | PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (NON-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAME | April 2021 | June 2021 | Allow | 2 | 0 | 0 | No | No |
| 17227217 | PERFUSION SYSTEM FOR HARVESTING BONE MARROW | April 2021 | March 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17281378 | COMPOSITIONS USEFUL FOR TREATING GM1 GANGLIOSIDOSIS | March 2021 | December 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 17275082 | POLYNUCLEOTIDES ENCODING BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX E1-ALPHA, E1-BETA, AND E2 SUBUNITS FOR THE TREATMENT OF MAPLE SYRUP URINE DISEASE | March 2021 | January 2026 | Allow | 58 | 3 | 1 | Yes | No |
| 17191650 | LIVER ORGANOID, USES THEREOF AND CULTURE METHOD FOR OBTAINING THEM | March 2021 | February 2026 | Allow | 59 | 3 | 1 | Yes | No |
| 17185545 | MICROCAPILLARY NETWORK BASED SCAFFOLD | February 2021 | September 2024 | Abandon | 43 | 3 | 0 | No | No |
| 17269479 | MEDICINE USING HSP47 INHIBITOR TO ENHANCE SENSITIVITY TO CHEMOTHERAPEUTIC AGENT | February 2021 | June 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17175114 | METHODS AND COMPOSITIONS FOR REDUCING ANTIBIOTIC ADMINISTRATION TO FARM ANIMALS | February 2021 | July 2025 | Allow | 53 | 3 | 0 | Yes | No |
| 17169765 | SYSTEM AND METHOD FOR CELL LEVITATION AND MONITORING | February 2021 | April 2024 | Allow | 38 | 2 | 1 | No | No |
| 17166547 | COMPOSITIONS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIZING ENTEROCOLITIS IN INFANTS OR YOUNG CHILDREN BORN BY C-SECTION | February 2021 | July 2025 | Allow | 53 | 5 | 0 | No | No |
| 17145877 | CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERY | January 2021 | December 2024 | Allow | 47 | 2 | 0 | No | No |
| 17127281 | METHODS FOR STABILIZING A BIOPROSTHETIC TISSUE BY CHEMICAL MODIFICATION OF ANTIGENIC CARBOHYDRATES | December 2020 | June 2024 | Allow | 42 | 2 | 1 | No | No |
| 17114685 | METHODS FOR PRODUCTION OF HUMAN HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | December 2020 | June 2024 | Allow | 42 | 2 | 1 | No | No |
| 17114896 | BIOLOGIC COMPOSITION AND METHOD OF USE | December 2020 | October 2025 | Allow | 58 | 4 | 1 | No | Yes |
| 17097023 | CULTURE MEDIA, CELL CULTURES AND METHODS OF CULTURING PLURIPOTENT STEM CELLS IN AN UNDIFFERENTIATED STATE | November 2020 | July 2025 | Allow | 56 | 4 | 1 | No | No |
| 17087571 | CELL EXPANSION | November 2020 | October 2024 | Allow | 48 | 1 | 1 | Yes | No |
| 17081991 | Porous Glucomannan Scaffolds and Methods for Producing the Scaffolds | October 2020 | July 2025 | Allow | 57 | 4 | 1 | Yes | No |
| 17080128 | METHOD FOR MANUFACTURING STEM CELL HAVING APPROPRIATE SIZE FOR INTRAVASCULAR ADMINISTRATION | October 2020 | November 2023 | Abandon | 37 | 2 | 0 | No | No |
| 17079821 | PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (NON-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAME | October 2020 | February 2021 | Allow | 4 | 0 | 0 | No | No |
| 17079720 | REVERSIBLE STENCILS FOR FABRICATING MICRO-TISSUES | October 2020 | September 2023 | Allow | 35 | 1 | 0 | No | No |
| 17072625 | COATED BIOLOGICAL COMPOSITION | October 2020 | October 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 17071693 | BIOLOGIC COMPOSITION AND METHOD OF MANUFACTURE | October 2020 | March 2023 | Allow | 29 | 1 | 1 | No | No |
| 17065335 | PROGENITOR CELLS OF MESODERMAL LINEAGE | October 2020 | October 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 16981699 | METHOD AND SYSTEM FOR HAIR REGROWTH USING 3D ORGANOID SYSTEM OF HAIR FOLLICLE STEM CELL | September 2020 | August 2025 | Abandon | 59 | 2 | 1 | No | No |
| 17017002 | XENOTRANSPLANTATION PRODUCTS AND METHODS | September 2020 | December 2020 | Allow | 3 | 0 | 0 | No | No |
| 17016937 | XENOTRANSPLANTATION PRODUCTS AND METHODS | September 2020 | November 2020 | Allow | 2 | 0 | 0 | No | No |
| 17013165 | Engineered Tissues for in vitro Research Uses, Arrays Thereof, and Methods of Making the Same | September 2020 | March 2025 | Allow | 54 | 2 | 1 | No | No |
| 16983190 | ACELLULAR BIOLOGIC COMPOSITION AND METHOD OF MANUFACTURE | August 2020 | March 2024 | Allow | 43 | 5 | 0 | Yes | No |
| 16966367 | TRANSFORMING GROWTH FACTOR BETA-RESISTANT NATURAL KILLER CELLS | July 2020 | January 2026 | Allow | 60 | 3 | 1 | Yes | No |
| 16939889 | WET PRESERVATION OF TISSUE | July 2020 | July 2022 | Allow | 24 | 4 | 1 | Yes | No |
| 16927390 | Lipofilling with ex-vivo expanded adipose tissue-derived stem cells for cosmetic breast filling or for facial filling and/or rejuvenation | July 2020 | August 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16960310 | PROCESSES FOR GENERATING TIL PRODUCTS ENRICHED FOR TUMOR ANTIGEN-SPECIFIC T-CELLS | July 2020 | May 2024 | Allow | 46 | 2 | 1 | No | No |
| 16911756 | METHOD FOR CULTURING BONE MARROW-DERIVED MESENCHYMAL STEM CELLS | June 2020 | September 2024 | Abandon | 51 | 3 | 0 | No | No |
| 16772712 | IN VITRO METHOD FOR CREATING A VIABLE CONNECTIVE TISSUE AND/OR OSSEOUS TISSUE | June 2020 | October 2022 | Allow | 28 | 1 | 1 | No | No |
| 16898224 | WET PRESERVATION OF TISSUE | June 2020 | April 2023 | Allow | 34 | 5 | 1 | Yes | No |
| 16769800 | Products and Methods for Assessing and Increasing Klotho Protein Levels | June 2020 | January 2024 | Abandon | 44 | 2 | 1 | Yes | No |
| 16765495 | METHOD FOR AGGREGATING CELL MASS AND DEVICE FOR AGGREGATING CELL MASS | May 2020 | August 2024 | Allow | 51 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PYLA, EVELYN Y.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 30.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PYLA, EVELYN Y works in Art Unit 1633 and has examined 260 patent applications in our dataset. With an allowance rate of 64.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner PYLA, EVELYN Y's allowance rate of 64.2% places them in the 25% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PYLA, EVELYN Y receive 2.93 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by PYLA, EVELYN Y is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +34.1% benefit to allowance rate for applications examined by PYLA, EVELYN Y. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.3% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 21.1% of cases where such amendments are filed. This entry rate is in the 26% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 18.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 26% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 57.1% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 56.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 72.7% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.